Article
Document
RDF description of Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis - http://irises.unipv.it/resource/item/90718
Information Content Entity
Academic Article
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
Generically Dependent Continuant